文献速递药物相互作用

维拉普生药代动力学特征:生物利用度、排泄、生物转化与药物相互作用潜力

Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential.
PubMed 文献 · Clin Pharmacokinet · 2018-01-01

两项在健康绝经后女性中开展的临床研究显示,维拉普生口服绝对生物利用度约60%,主要经肝脏代谢后由粪便排泄,CYP3A4在其代谢中起关键作用;与强CYP3A4抑制剂伊曲康唑合用可使维拉普生暴露量增加6.2倍。

要点

  • 维拉普生口服绝对生物利用度约60%,主要经粪便排泄(73.5%)。
  • CYP3A4介导维拉普生代谢,伊曲康唑使其暴露量增加6.2倍。
  • 临床合用时需关注强CYP3A4抑制剂对维拉普生暴露的影响。

核心结论

  • 维拉普生主要在肝脏代谢为多种代谢物,主要经粪便排泄,CYP3A4在其代谢中起关键作用。
  • 强CYP3A4抑制剂伊曲康唑可显著增加维拉普生暴露量。

研究设计与样本

  • 研究1:6名健康绝经后女性单次口服5 mg [14C]标记维拉普生,测定药代动力学、质量平衡和代谢物谱。
  • 研究2:14名健康绝经后女性单次口服4 mg维拉普生,分别在不合用和合用强CYP3A4抑制剂伊曲康唑(200 mg/天)条件下测定药代动力学。
  • 研究2另给予静脉微示踪剂量维拉普生以测定绝对生物利用度、清除率和分布容积。

主要发现

  • 血浆中主要单一化合物为维拉普生,未检测到超过总药物相关AUC 10%的血浆代谢物。
  • 维拉普生口服绝对生物利用度约60%,平均清除率约7 L/h,稳态分布容积约360 L。
  • 排泄主要经粪便(73.5 ± 3.70%剂量;尿液13.1 ± 1.71%;总回收率86.6 ± 2.81%),主要以代谢物形式排出,排泄物中仅发现少量原型药物。
  • 维拉普生与伊曲康唑合用时,维拉普生暴露量增加6.2倍(90%置信区间5.4-7.2)。

临床怎么用

  • 临床合用强CYP3A4抑制剂时应关注维拉普生暴露量显著增加的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: In-vitro data suggest that clearance of vilaprisan is mediated by cytochrome P450 3A4 (oxidation) and aldoketoreductases (reduction). To fully understand the elimination and biotransformation pathways of vilaprisan, a selective progesterone receptor modulator, and to quantify the impact of cytochrome P450 3A4 inhibition on the pharmacokinetics of vilaprisan, two clinical studies in healthy postmenopausal women were conducted. METHODS: In study 1, pharmacokinetics, mass balance, and metabolite patterns were determined after single oral administration of 5 mg of [14C]-labeled vilaprisan in six subjects. In study 2, pharmacokinetics were determined after single oral administration of 4 mg of vilaprisan without and with concomitant administration of the strong cytochrome P450 3A4 inhibitor itraconazole (200 mg/day) in 14 subjects. In addition, a microtracer dose of vilaprisan was given intravenously to determine absolute bioavailability, clearance, and volume of distribution. RESULTS: The dominant single compound in plasma was vilaprisan. No plasma metabolites exceeding 10% of total drug-related area under the concentration-time curve were detected. The absolute oral bioavailability of vilaprisan was ~ 60%. The mean clearance was ~ 7 L/h and the volume of distribution at steady state was ~ 360 L. Excretion occurred primarily via feces (73.5 ± 3.70% of dose; urine: 13.1 ± 1.71%; total recovery: 86.6 ± 2.81%), mostly in a metabolized form. Only small amounts of the parent drug were found in excreta. When vilaprisan was administered together with itraconazole, exposure to vilaprisan was increased 6.2-fold (90% confidence interval 5.4-7.2). CONCLUSIONS: Vilaprisan is predominantly metabolized in the liver to a complex variety of metabolites, which are mainly excreted with feces. The pivotal role of cytochrome P450 3A4 in the metabolism of vilaprisan was confirmed. CLINICAL TRIAL REGISTRATION: EudraCT numbers 2013-000707-16 (mass balance study) and 2014-004929-41 (drug-drug interaction/microtracer study); NCT02456129 (drug-drug interaction/microtracer study).

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Schultze-Mosgau MH, Höchel J, Prien O, et al. Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential. Clin Pharmacokinet. 2018. PMID: 29330782. doi:10.1007/s40262-017-0607-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。